![](https://endpts.com/wp-content/uploads/2023/04/Rob-Davis-Merck-Galien-Foundation-tile.jpg)
Rob Davis, Merck CEO (Credit: The Galien Foundation)
Merck brings Harpoon Therapeutics and its PhI/II T cell engager into the fold for $680M
Merck has struck a deal to buy Harpoon Therapeutics for $680 million, beefing up its oncology pipeline with a portfolio of T cell engagers. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.